Cargando…
An update on the novel and approved drugs for Alzheimer disease
INTRODUCTION: Given the severity of the condition and the increasing number of patients, developing effective therapies for Alzheimer's disease has become a significant necessity. Aggregation of Amyloid-Beta (Aβ) plaques and Tau Protein Tangles in the brain's nerve tissue are two of the mo...
Autores principales: | Alhazmi, Hassan Ahmad, Albratty, Mohammed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805975/ https://www.ncbi.nlm.nih.gov/pubmed/36601504 http://dx.doi.org/10.1016/j.jsps.2022.10.004 |
Ejemplares similares
-
Analytical Techniques for the Characterization and Quantification of Monoclonal Antibodies
por: Alhazmi, Hassan A., et al.
Publicado: (2023) -
Therapeutic insights elaborating the potential of retinoids in Alzheimer’s disease
por: Behl, Tapan, et al.
Publicado: (2022) -
Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
por: Varadharajan, Ashvin, et al.
Publicado: (2023) -
Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
por: Nunes, Débora, et al.
Publicado: (2022) -
Demystifying the Neuroprotective Role of Neuropeptides in Parkinson’s Disease: A Newfangled and Eloquent Therapeutic Perspective
por: Behl, Tapan, et al.
Publicado: (2022)